Results 181 to 190 of about 16,590,594 (260)

Research Progress on Mechanisms of Immune Tolerance Induced by Hepatitis B Surface Antigen in Chronic HBV Infection. [PDF]

J Immunol Res
Wang L.
europepmc   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score-Matched Study Using Linear Mixed-Effects Models. [PDF]

Aliment Pharmacol Ther
Kumada T, Atsukawa M, Itokawa N, Arai T, Toyoda H, Tsubota A, Watanabe T, Chuma M, Matsuura K, Hiraoka A, Tada T, Takaguchi K, Kato K, Abe H, Tani J, Ishikawa T, Ogawa C, Asano T, Oikawa T, Matsumoto Y, Akita T, Tanaka J.   +21 more
europepmc   +1 more source

Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin‐3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B

Hepatology Research, EarlyView.
We carried out proteomic analysis of serum extracellular vesicles to identify biomarkers predictive of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B receiving nucleos(t)ide analog therapy. Candidate proteins identified through proteomic analysis were subsequently quantified in serum by ELISA.
Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto, Satoshi Shigeno, Yuta Myojin, Kazuki Maesaka, Kumiko Shirai, Yuki Makino, Yuki Tahata, Yoshinobu Saito, Takahiro Kodama, Ryotaro Sakamori, Jun Adachi, Tomomi Yamada, Tetsuo Takehara   +21 more
wiley   +1 more source

Overcoming Immunotolerance in Chronic Hepatitis B: Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor-Based Immunotherapy in Achieving Hepatitis B Surface Antigen Seroclearance. [PDF]

MedComm (2020)
Geng S, Yang F, Jia H, Zhao G, Zhao W, Yu J, Zhu H, Cai H, Yang L, Zhang S, Yu F, Jin X, Zhang S, Wang X, Yang Y, Zhang J, Wang B.   +16 more
europepmc   +1 more source

On‐Treatment Reassessment of Type IV Collagen 7S and M2BPGi‐Qt Improves Long‐Term Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis B

Hepatology Research, EarlyView.
One‐year reassessment of type IV collagen 7S, supported by quantitative M2BPGi‐Qt assessment, helped refine long‐term hepatocellular carcinoma risk stratification in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy. On‐treatment 4COL7S emerged as a novel marker of residual fibrosis‐related HCC risk.
Kazumi Yamasaki, Hideko Kozuru, Tomoko Sato, Tomoyuki Suehiro, Yasuhide Motoyoshi, Yuki Kugiyama, Akira Saeki, Shinya Nagaoka, Atsumasa Komori, Hiroshi Yatsuhashi   +9 more
wiley   +1 more source

Long-Term Clinical Outcomes of Kidney Transplantation from Hepatitis B Surface Antigen (HBsAg)-Positive Donors to HBsAg-Negative Recipients: A Systematic Review and Meta-Analysis of Real-World Studies. [PDF]

J Clin Med
Liang C, Luo Y, Yin S, Song T, Lin T.
europepmc   +1 more source

Cisterna Chyli Dilation Is a Risk Factor for Liver Nodules and Hepatocellular Carcinoma in Fontan‐Associated Liver Disease: Pathophysiological Role of Lymphatic Dysfunction

Hepatology Research, EarlyView.
ABSTRACT Aim In Fontan‐associated liver disease (FALD), chronic congestion often confounds conventional fibrosis markers, complicating surveillance for hepatocellular carcinoma (HCC). Although lymphatic dysfunction is fundamental to Fontan physiology, its contribution to hepatocarcinogenesis remains unclear.
Koji Imoto, Masatake Tanaka, Takeshi Goya, Yuuki Azuma, Tomonobu Hioki, Yusuke Morita, Keisuke Sakaguchi, Nobuhiro Fujita, Takamori Kakino, Ayako Ishikita, Kenichiro Yamamura, Ichiro Sakamoto, Kousei Ishigami, Kohtaro Abe, Yoshihiro Ogawa   +14 more
wiley   +1 more source

Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B. [PDF]

Front Cell Infect Microbiol
Peng X, Chang Y, Wu J, Zhu J, Hu P, Ren H, Xu H, Zhao R, Qin T.   +8 more
europepmc   +1 more source

Cyclin‐dependent kinase 4/6 (CDK4/6) inhibitor‐induced hepatotoxicity and its resolution: a study of seven cases

Histopathology, EarlyView.
CDK4/6 inhibitor‐induced liver injury represents a clinically significant and histologically distinctive form of drug‐induced hepatotoxicity, most commonly encountered with ribociclib. The predominant pattern is severe acute hepatocellular injury, frequently accompanied by lymphocytic cholangitis, a combination that, in the appropriate clinical context,
Sunayana Misra, Lisa Centeno, Dupinder Singh, Romil Saxena, Rifat Mannan   +4 more
wiley   +1 more source